Absolute bioavailability of clarithromycin after oral administration in humans
- 1 May 1992
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 36 (5) , 1147-1150
- https://doi.org/10.1128/aac.36.5.1147
Abstract
The absolute bioavailability of clarithromycin, a new macrolide antimicrobial agent, was assessed in a three-way, randomized, single-dose, crossover study conducted with 22 healthy volunteers, 19 of whom provided analyzable study data. The bioavailability parameters of two 250-mg oral tablet formulations were calculated with reference to an identical dose administered by intravenous infusion of the lactobionate salt. After adjustment for formulation potency, the mean absolute bioavailabilities of the two oral formulations were 52 and 55%, on the basis of the appearance of parent compound in the systemic circulation. Metabolite peak concentration and area under the plasma concentration-time curve data after oral dosing were generally greater than those after intravenous infusion, suggesting that marked first-pass metabolism of clarithromycin occurs after oral administration. Pharmacokinetic analysis of the parent drug and the active 14-hydroxy metabolite data suggests complete (or nearly complete) absorption of the drug after oral administration.Keywords
This publication has 15 references indexed in Scilit:
- Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1991
- Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophagesAntimicrobial Agents and Chemotherapy, 1990
- METABOLISM AND DISPOSITION OF CLARITHROMYCIN IN MAN1990
- Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humansAntimicrobial Agents and Chemotherapy, 1990
- In vitro activity of tosufloxacin (A-60969) and clarithromycin (A-56268, TE-031) against resistantHaemophilus influenzae, Streptococcus pneumoniae andBranhamella catarrhalis isolatesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycinAntimicrobial Agents and Chemotherapy, 1989
- In-vitro activity of clarithromycin (A-56268; TE-031) against Gram-positive bacteriaJournal of Antimicrobial Chemotherapy, 1989
- THE AREA UNDER THE CURVE OF METABOLITES FOR DRUGS AND METABOLITES CLEARED BY THE LIVER AND EXTRAHEPATIC ORGANS - ITS DEPENDENCE ON THE ADMINISTRATION ROUTE OF PRECURSOR DRUG1985
- Metabolite pharmacokinetics: The area under the curve of metabolite and the fractional rate of metabolism of a drug after different routes of administration for renally and hepatically cleared drugs and metabolitesJournal of Pharmacokinetics and Biopharmaceutics, 1981
- CSTRIP, a Fortran IV Computer Program for Obtaining Initial Polyexponential Parameter EstimatesJournal of Pharmaceutical Sciences, 1976